
Nuvalent, Inc. (NASDAQ:NUVL) on Monday reported topline results from its ALKOVE-1 Phase 1/2 trial.
The study evaluated neladalkib in tyrosine kinase inhibitor (TKI)-pretreated patients with advanced ALK-positive non-small cell lung cancer (NSCLC). The company said the recommended Phase 2 dose was set at 150 mg once daily, selected during the Phase 1 dose-escalation stage.